Neovacs’s lead project, IFN-Kinoid (IFN-K) for lupus, started a 178-patient EU, US and RoW Phase II in Q315. It expects data by mid-2017. This is based on clinical response and measurement of the interferon signature (IS), a diagnostic marker of lupus. CKD, a leading Korean pharmaceutical company, partnered the product for Korea in 2015; marketing may start in 2018. Neovacs plans to partner IFN-K, implying possible launches in 2021. VEGF-Kinoid for cancer and AMD could start Phase I in
01 Aug 2016
Lupus signature
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Lupus signature
Neovacs’s lead project, IFN-Kinoid (IFN-K) for lupus, started a 178-patient EU, US and RoW Phase II in Q315. It expects data by mid-2017. This is based on clinical response and measurement of the interferon signature (IS), a diagnostic marker of lupus. CKD, a leading Korean pharmaceutical company, partnered the product for Korea in 2015; marketing may start in 2018. Neovacs plans to partner IFN-K, implying possible launches in 2021. VEGF-Kinoid for cancer and AMD could start Phase I in